Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors

In the last few years, the treatment of patients with non-small cell lung cancer (NSCLC) has impressively benefitted from immunotherapy, in particular from the inhibition of immune checkpoints such as programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1). However, despite the sig...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Thorac Dis
Hauptverfasser: Berland, Léa, Heeke, Simon, Humbert, Olivier, Macocco, Adam, Long-Mira, Elodie, Lassalle, Sandra, Lespinet-Fabre, Virginie, Lalvée, Salomé, Bordone, Olivier, Cohen, Charlotte, Leroy, Sylvie, Hofman, Véronique, Hofman, Paul, Ilié, Marius
Format: Artigo
Sprache:Inglês
Veröffentlicht: AME Publishing Company 2019
Schlagworte:
Review Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6353746/
https://ncbi.nlm.nih.gov/pubmed/30775030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.11.102
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge